Lisinopril 1 mg/mL oral suspension

Oral suspension of the listed composition. The IWK sheet does not specify colour/odour/viscosity.

References: [1]

ACE inhibitor; cardiovascular use.
Active-drug context from another product’s labelling; it does not establish stability or dosing of this compounded preparation.

References: [2]

No numerical QC criteria are given. Define local homogeneity, redispersibility and release criteria.

References: [1]

For the finished product the source specifies:
Amber plastic bottle, protected from light. Refrigerate. No numerical temperature range stated.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

No specific information is established by the consulted sources. Complete this before local approval where critical to this preparation.

References: [1]

Complete formula-specific PPE is not specified. Select gloves, eye protection and exposure controls using the exact materials’ SDS and the local risk assessment.
Supplementary AEMPS framework: clean long-sleeved laboratory clothing, hair covering and dedicated footwear/overshoes. Powder handling requires suitable eye/respiratory protection; change gloves with activity or damage. Select the exact type/material using SDS and risk assessment.

References: [1] · [3]

A complete formula-specific hazard classification is not established. Assess potency, dust/aerosol, allergens, solvents, microbial risk and cross-contamination using the actual materials and process. Absence of a flag does not establish absence of hazard.

References: [1]

Follow the addition sequence, temperatures and times stated under Preparation Procedure. The specific monograph is not a complete qualification of the local facility/equipment.

References: [1]

Source states 90-day stability under those conditions.
The source period applies to its exact composition, method and packaging. It is not this batch’s expiry date and cannot be transferred to another vehicle/strength. Calculate the actual date in the blank batch record.

References: [1]

No separate base is identified in the dependency register. Check any commercial vehicles/compound excipients listed in the formula.

References: [1]

Indicative checklist derived from the method: Balance of suitable resolution, Containers and mixing tools compatible with the materials. Selection/qualification is defined locally.

References: [1]

Pulverise tablets. Levigate with about 10 mL vehicle, dilute progressively, transfer to a graduate and make to final volume. Mix and package.

References: [1]

IWK sheet 20/06/2017; public index reports NAPRA review. Stated stability is not an approved local BUD. Retain the exact vehicle and assess supporting evidence.

References: [1]

Amber plastic bottle.

References: [1]

No numerical QC criteria are given. Define local homogeneity, redispersibility and release criteria.

References: [1]

Amber plastic bottle, protected from light. Refrigerate. No numerical temperature range stated.

References: [1]

No additional special directions are established beyond the source route, storage and notes. Complete patient details, dose and directions from the prescription.

References: [1]

Lisinopril 1 mg/mL oral suspension
Strength/variant: __________ Quantity: __________
Batch: __________ Prepared: __________ Use by: __________
Από του στόματος / Oral use
Dose/directions: __________
Storage: Amber plastic bottle, protected from light. Refrigerate. No numerical temperature range stated.
Shake before use.

References: [1]